Medicare AdvantagePrior AuthMedium impact
Cibinqo® (abrocitinib) (Revised)
Humana·Dermatology, Pharmacy·Medicare Advantage
Effective date
Dec 17, 2025
We identified it
Jun 25, 2026
Summary
Humana revised its Cibinqo (abrocitinib) prior authorization policy effective December 17, 2025. This is a JAK inhibitor for moderate-to-severe atopic dermatitis in patients 12+ years old. The policy requires prior authorization and mandates documented failure/contraindication/intolerance with both Dupixent AND Rinvoq before approval. Claims will be denied if these prerequisites are not met.
Action Required
By December 17, 2025: Billing and prior authorization teams must implement the updated Cibinqo criteria in the authorization system. Specifically: (1) Providers must document that the patient has moderate-to-severe atopic dermatitis; (2) Verify patient age is 12 or older; (3) Most critically—obtain documentation showing prior therapy failure, contraindication, or intolerance with BOTH Dupixent AND Rinvoq before submitting authorization requests. Update PA submission templates and EMR decision support to prompt providers for this dual-therapy documentation. Train billing and clinical staff on the three mandatory criteria. Communicate changes to dermatology providers. Any Cibinqo claims submitted without documented prior failure of both Dupixent and Rinvoq will be denied at authorization or claim level.